<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714451</url>
  </required_header>
  <id_info>
    <org_study_id>2000023930</org_study_id>
    <nct_id>NCT03714451</nct_id>
  </id_info>
  <brief_title>Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes</brief_title>
  <official_title>Investigating the Effect of Onyx Sorghum on Blood Glucose in Individuals With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of onyx sorghum on blood glucose levels in patients with type 2
      diabetes (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The plan is to study 24 participants with T2DM, who are otherwise healthy. The study will be
      double-blinded and randomized. Participants will first attend a screening visit (Visit #1) to
      determine eligibility. Then, eligible participants will be asked to wear a FreeStyle Libre
      Pro continuous glucose monitor (CGM) for up to 14 days (Visit #2). After this 14-day CGM
      session, participants will be randomly assigned (1:1) to one of two groups that will receive:
      1) food products containing onyx sorghum (Onyx Group) or 2) food products with wheat flour
      (Control Group). The diet intervention will last a total of 28 days. Participants will have
      weekly visits to pick up food and bi-weekly blood draws (no more than 20mL at each visit).
      They will also be asked to wear the CGM throughout the diet intervention and will record
      their food intake in a daily food diary to confirm that the diet intervention is being
      followed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blinded randomized</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycemic variability</measure>
    <time_frame>day 1</time_frame>
    <description>The continuous glucose monitoring (CGM) consists of a sensor that measures glucose levels from the interstitial tissue. Changes in glucose levels from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycemic variability</measure>
    <time_frame>14 days</time_frame>
    <description>The continuous glucose monitoring (CGM) consists of a sensor that measures glucose levels from the interstitial tissue. Changes in glucose levels from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycemic variability</measure>
    <time_frame>day 28</time_frame>
    <description>The continuous glucose monitoring (CGM) consists of a sensor that measures glucose levels from the interstitial tissue. Changes in glucose levels from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>day 1</time_frame>
    <description>change in weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>day 14</time_frame>
    <description>change in weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>day 28</time_frame>
    <description>change in weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>upon screening</time_frame>
    <description>change in BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>day 1</time_frame>
    <description>change in BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>day 14</time_frame>
    <description>change in BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>day 28</time_frame>
    <description>change in BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels</measure>
    <time_frame>upon enrollment</time_frame>
    <description>change in blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels</measure>
    <time_frame>day 1</time_frame>
    <description>change in blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels</measure>
    <time_frame>day 14</time_frame>
    <description>change in blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose levels</measure>
    <time_frame>day 28</time_frame>
    <description>change in blood glucose levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Eating behavior</measure>
    <time_frame>day 1</time_frame>
    <description>measure of food provided and returned</description>
  </other_outcome>
  <other_outcome>
    <measure>Eating behavior</measure>
    <time_frame>day 14</time_frame>
    <description>measure of food provided and returned</description>
  </other_outcome>
  <other_outcome>
    <measure>Eating behavior</measure>
    <time_frame>day 28</time_frame>
    <description>measure of food provided and returned</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Onyx Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat Flour Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with T2DM will receive food products with wheat flour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>onyx sorghum</intervention_name>
    <description>The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.</description>
    <arm_group_label>Onyx Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>whole wheat flour</intervention_name>
    <description>Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.</description>
    <arm_group_label>Wheat Flour Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 30-65 years

          -  A1c &lt; 8.5%

          -  BMI &gt; 18.5

        Exclusion Criteria:

          -  known malignancy, anemia, kidney disease, and/or liver disease

          -  untreated thyroid disease

          -  uncontrolled hypertension

          -  initiation of any anti-diabetes medications within the last 3 months

          -  greater than 5% change in weight in the last 3 months

          -  current or recent steroid use in the last 3 months

          -  for women: pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renata Belfort de Aguiar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine Department of Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renata Belfort De Aguiar, MD, PhD</last_name>
    <phone>203-785-7474</phone>
    <email>renata.aguiar@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Leventhal, DNP, APRN</last_name>
    <phone>475-331-8966</phone>
    <email>jessica.leventhal@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Belfort De Aguiar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Belfort De Aguiar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Belfort De Aguiar, Md, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

